Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amgen Wins First EU Avastin Biosimilar Approval, But When Will It Launch?

Executive Summary

Partners Amgen and Allergan have become the first biosimilar developers to win EU approval for a copycat version of Roche's Avastin; commercialization preparation is underway but predicting a launch date for the product is more complicated.

Advertisement

Related Content

Two Orphans And An Avastin Biosimilar Among EU Approval Recommendations
Pharma Q2 Results Preview: AstraZeneca, Roche, Merck And BMS
Pfizer’s Dacomitinib And More Biosimilar Hopefuls Among New EMA Filings

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC100233

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel